Back

Warfarin and aspirin versus warfarin alone in patients with HeartMate 3 left ventricular assist device: a systematic review and meta-analysis.

12 May 2024 (11:00 - 11:45)
Organised by: Logo
Congress Presentation Part of: Chronic heart failure - treatment 6 Ventricular Assist Devices HFA Premium Access Heart Failure 2024 Heart Failure Association (HFA)

About the speaker

Photo
Mr Lucas Rezende De Freitas

(Brazil)

6 More presentations in this session

Presentation thumbnail
Histological profiling, viral analysis, and follow-up of inflammatory cardiomyopathy in adults supported by long-term left ventricular assist device therapy
Doctor M. Ruiz Cano (Bad Oeynhausen, DE)
Abstract Slides Video
Presentation thumbnail
The impact of sodium glucose transporter 2 inhibitors on cardiac remodeling in a large cohort of unselected patients
Doctor V. Copeland (Ramat Gan, IL)
Abstract Slides Video
Presentation thumbnail
Impact of hemodynamic optimization on reducing pulmonary pressures and adverse clinical events in left ventricular assist device recipients with elevated pulmonary vascular resistance
Professor M. Kim (Seoul, KR)
Abstract Slides Video
Presentation thumbnail
Impact of an extended infectiological standard operating procedure on the outcome of patients with VAD-associated infections
Mr Y. Streef (Berlin, DE)
Abstract Slides Video
Presentation thumbnail
Clinical and echocardiographic effects of vericiguat therapy in advanced heart failure patinets undergoing LVAD support
Associate Professor G. Poglajen (Ljubljana, SI)
Abstract Slides Video

Access the full session

Session thumbnail
Chronic heart failure - treatment 6

The Event

Event poster

Heart Failure 2024

12 May 2024 11:00 CET
You may be interested in
thumbnail
Congress Presentation
Efficacy and safety of antithrombotic regimens in patients with durable left ventricular assist devices: a systematic review and bayesian network meta-analysis
thumbnail
Congress Presentation
Outcomes with aspirin avoidance after implantation of a Fully Magnetically Levitated LVAD in patients with coronary, cerebral or peripheral vascular disease: the ARIES HM3 randomized clinical trial
thumbnail
Congress Presentation
Reducing residual risk in left ventricular assist device carriers: lessons from ARIES-HM3 trial

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources